ClearOne is trading 200.27% up now at $11.05 after shareholders approved issuing 12.5 million new common shares to Vivani Medical for the Cortigent merger.
- The consent represented approximately 61.3% of voting stock, removing a key transaction condition and significantly de-risking the merger timeline.
- Additional developments included warrant cancellation and a new CFO employment agreement, reinforcing confidence in ClearOne’s planned neurostimulation-focused transformation.